Sound Bioventures is a Venture Capital firm that Invests in private clinical stage biotherapeutics companies in Europe and USA. The fund has a geographic footprint on both sides of the Atlantic and will support the clinical development of novel medicines for diseases of high unmet medical need.
Employees: 1-10
Founded date: 2021
Investment Type: Venture Capital
Portfolio 2
| Date | Name | Website | Total Raised | Location |
| 03.05.2023 | ARTHEx Bio... | arthexbiotech.com | $51.32M | Spain, l'H... |
| 14.03.2023 | Teitur Tro... | teiturtrophics.com | $30.02M | Denmark, C... |
Mentions in press and media 10
| Date | Title | Description |
| 11.01.2025 | AnaCardio's €19 Million Leap: A New Dawn for Heart Failure Treatment | In the world of biopharmaceuticals, every funding round can feel like a heartbeat—vital and pulsating with potential. AnaCardio, a clinical-stage startup based in Stockholm, has just secured €19 million (approximately USD 19 million) to adv... |
| 10.01.2025 | AnaCardio pumps €19 million into heart failure treatment innovation | AnaCardio, a clinical-stage biopharmaceutical startup headquartered in Stockholm, has secured €17.8 million in a Series A extension round to develop their drug candidate AC01. The financing was co-led by Novo Holdings, Pureos Bioventures, a... |
| 09.01.2025 | AnaCardio raises USD 19 million to advance first-in-class drug candidate AC01 for heart failure | AnaCardio raises USD 19 million to advance first-in-class drug candidate AC01 for heart failure Thu, Jan 09, 2025 09:00 CET Report this content Reports positive results from phase 1b study of AC01 in patients with heart failure and reduced ... |
| 13.08.2024 | Artax Biopharma completes patient recruitment in Phase 2a trial with first-in-class Nck modulator AX-158 | AX-158 has broad potential to treat many autoimmune diseases without causing immunosuppression Psoriasis biomarker panel and PASI scores expected later this year CAMBRIDGE, Mass., Aug. 13, 2024 /PRNewswire/ -- Artax Biopharma, Inc., a clini... |
| 25.05.2023 | VarmX raises €30M to develop therapeutic proteins that restore hemostasis in bleeding patients | Leiden-based VarmX, a biotech company developing “innovative” approaches for the reversal of anticoagulation (also known as blood thinners), announced on Thursday that it has secured an additional €30M in a Series B2 round of funding. The D... |
| 12.05.2022 | Columbus VP cierra la financiación de $26M en Artax Biopharma | 12/05/2022 Nota de prensa COLUMBUS CIERRA LA FINANCIACIÓN EN LA EMPRESA ARTAX BIOPHARMA. La firma de capial riesgo (venture capital) Columbus Venture Partners cierra la financiación de 26 millones de dólares en la empresa Artax Biopharma... |
| 07.01.2022 | Debut Sound Bioventures fund closes on €110m to target Scandinavian, US biotech | Life sciences-focused Swedish venture capital house Sound Bioventures has hit a €110m final close for its debut fundra |
| 04.01.2022 | Novo Holdings, Saminvest, Vækstfonden, EIF Invest in Sound Bioventures Fund I | Novo Holdings, Saminvest, Vækstfonden and the European Investment Fund and other private investors, invested in Sound Bioventures Fund I in the first close of €110m. Sound Bioventures will be investing in private biotech companies and will ... |
| 04.01.2022 | Scandinavian VC firm Sound Bioventures raises €110M for new biotherapeutics venture fund | Scandinavia-based Sound Bioventures, a VC fund investing in about-to-be clinical or clinical stage private companies in Europe and US developing therapies in specialty therapeutics areas, announced the first close of its first fund at €110M... |
| - | Scandinavia’s biotech-focused VC fund Sound Bioventures opens with €110 million | Malmö/Copenhagen-based life sciences VC firm Sound Bioventures has announced the first close of its inaugural fund at €110 million. The new fund is targeting European and US-based biotech companies that are working on medicines to treat orp... |